Cutting-Edge Concepts in HIV Care: Long-Acting Therapies

In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including:

• Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)
• Risk factors for virologic failure of LA CAB + RPV
• The ATLAS-2M study
• Combined clinical trials of LA CAB + RPV
• Practical considerations for LA CAB + RPV
• Implementation of LA CAB + RPV
• Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension study
• Supporting candidates for LA antiretroviral therapy (ART)
• Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San Francisco
• Future LA ART
• The investigational LA HIV capsid inhibitor lenacapavir (LEN)
• LEN resistance from the CAPELLA and CALIBRATE studies
• LEN injection-site reactions in the CAPELLA and CALIBRATE studies